Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sopharma AD (SPH.WA)
Sofia, BG
Sopharma AD, an international pharmaceutical company founded in Sofia, Bulgaria, in 1933, specializes in the research, development, manufacturing, and commercialization of a wide array of healthcare products. Its offerings span medicinal substances, finished drug formulations, veterinary vaccines, infusion solutions, and disposable plastic medical devices for both human and animal health, in addition to food supplements. The company's diverse product portfolio addresses numerous therapeutic categories, including cardiology, gastroenterology, pain management, cough and cold remedies, immunology and dermatology, respiratory conditions (like asthma), neurology and psychiatry, urology, and gynecology. Key products include Carsil for gastrointestinal issues, the analgesic Tempalgin, Tabex for smoking cessation, Tribestan to support sexual system functions, Broncholytin for coughs, the common pain reliever Analgin, Nivalin for peripheral nervous system disorders, and Methylprednisolon for severe allergies and critical medical situations. Beyond its core pharmaceutical business, Sopharma AD engages in a variety of other ventures. These include providing secondary packaging services for pharmaceuticals, leasing real estate, and operating in the retail sector for medicines and medical equipment. The company also handles the cultivation, collection, and trade of herbs and medicinal plants. Furthermore, it is involved in the trading, transport, and packaging of radioactive materials and nuclear equipment for medical applications, as well as household electronics and electrical equipment. Sopharma AD also offers market and public opinion research, provides franchising and know-how, and participates in various consulting and non-pharmaceutical activities, such as the production of veterinary vaccines and infusion solutions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.23% | -3.23% | -2.99% | +4.00% | -38.82% | -37.85% | -47.65% | -51.25% | -4.29% | +29.78% | +4.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+22.6% ★ Q1'26: +7.8% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-100.0% Q1'26: -50.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+5.4% ★ Q1'26: +2.4% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+6.9% ★ Q1'26: +10.5% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+10.6% ★ Q1'26: +17.3% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+108.1% Q1'26: +231.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×2.38× Q1'26: 1.57× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-08 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-05 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-02 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-06-01 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-29 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ognian Ivanov Donev | Chairman, Chief Executive Officer & MD | 723.2K | male |
| Boris Anchev Borisov | Chief Financial Officer & Financial Director | — | male |
| E. Krasteva | Director of Advertising & Corporate Communications | — | — |
| E. Mihailova | Head of Production Division | — | — |
| Iordanka Nikolova Petkova | Chief Accountant | — | — |
| Kotzeva | Head of Drug Safety Department | — | — |
| Lyudmila Bondzhova | Head of Reporting Department | — | — |
| Pelagia Stefanova Viatcheva | Director of Investor Relations | — | — |
| Alexandar Yotov | Head of Legal Department | — | male |
| S. Katzarova | Head of Regulatory Affairs Bulgaria & Third Markets Division | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPH.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
